Intellia's CRISPR Gene Therapy Achieves 87% Reduction in Hereditary Angioedema Attacks in Phase 3 Trial
Key Insights
Intellia Therapeutics' CRISPR-based treatment lonvo-z (search) demonstrated an 87% reduction in swelling attacks compared to placebo in an 80-patient Phase 3 trial for hereditary angioedema (search).
The single-dose, in vivo gene editing therapy resulted in 62% of patients being completely attack-free six months after treatment, compared to 11% in the placebo group.
If approved, lonvo-z (search) would become the second FDA-approved CRISPR medicine and the first to edit DNA directly inside the body, with Intellia planning to complete regulatory filing in the second half of 2026.
Intellia Therapeutics announced Monday that its CRISPR-based gene editing treatment achieved dramatic results in a pivotal Phase 3 trial for hereditary angioedema (search) (HAE), a rare genetic disorder characterized by potentially life-threatening swelling attacks. The therapy, known as lonvo-z (search) (lonvoguran ziclumeran (search)), reduced attack rates by 87% compared to placebo in the 80-patient study.
Breakthrough Results in Rare Disease Treatment
In the Phase 3 trial, patients with hereditary angioedema (search) who received the single-dose treatment experienced significant clinical improvements. Just over 60% of treated patients were entirely attack-free over the study period, compared to only 11% of those receiving placebo. Six months after treatment, 62% of patients remained free from attacks and weren't using other therapies.
The treatment uses Nobel Prize-winning CRISPR technology to edit DNA and turn off the gene that controls production of a peptide that's overactive in people with hereditary angioedema (search). Unlike existing therapies, lonvo-z (search) is administered once through an hours-long infusion, making the genetic edits directly in the liver.
First In Vivo CRISPR Therapy to Reach Phase 3
If approved, lonvo-z (search) would represent a significant milestone as the second FDA-approved CRISPR-based medicine, following Vertex Pharmaceuticals' Casgevy for sickle cell disease. Crucially, it would be the first in vivo CRISPR treatment, meaning it edits patients' DNA directly inside the body rather than requiring cells to be removed, edited externally, and reinfused.
"When you think about where we started with Crispr, just 12 years ago with some of the fundamental insights, I think there was a lot of talk about what might be possible, and we've had reports along the way in terms of milestones, but this is the first Phase 3 data in any indication with in vivo Crispr where you're actually changing a gene that causes disease," said Intellia CEO John Leonard.
Safety Profile and Regulatory Timeline
Intellia described the safety and tolerability of the treatment as "favorable," with the most common side effects being infusion-related reactions, headaches, and fatigue. This safety data was closely monitored following a previous incident where a patient in a separate Intellia trial died from liver toxicity.
The company has initiated a rolling submission with the FDA and plans to complete the filing in the second half of this year. If approved, Intellia expects to launch the treatment in the U.S. in the first half of next year.
Market Competition and Long-term Effects
Upon approval, lonvo-z (search) will compete with approximately a dozen other chronic drugs for HAE treatment. However, Leonard emphasized key advantages of the gene editing approach, noting that unlike some gene therapies that have faced questions about durability, Intellia hasn't observed any diminishing effects in almost six years of follow-up data.
"I think this is a tipping point for the disease and tipping point for Crispr-based in vivo therapy where you can make a change [and] it's permanent," Leonard said. "And, as far as we can tell, we don't have a single patient in this program or other program where there's been any waning of the effect of what we did to the gene or the effect of what we've seen with the clinical aspects of the disease itself."
Despite the promising results, Leonard remains cautious about calling the treatment a functional cure, though he acknowledges the potential for permanent therapeutic effects through targeted gene modification.